Clinical trials: Advanced Esophageal Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Esophageal Cancer
a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent
Esophageal cancer is common in some areas , ranking as the fourth leading cause of death from cancer in China and sixth worldwide.
- Trial name
- NCT01054274
- Testing
- novel stent, conventional covered stent
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Southeast University, China
Locally Advanced Esophageal Squamous Cell Carcinoma
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities.
- Trial name
- EC-CRT-007 (NCT06187597)
- Testing
- S-1, Toripalimab, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Gastric Adenocarcinoma
Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer
evaluate efficacy and safety of neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer
- Trial name
- NCT06496789
- Testing
- Serplulimab+SOX
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients enrolled in Phase Ib PALACE-1(NCT03792347).The results…
- Trial name
- PALACE-2 (NCT04435197)
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Ruijin Hospital
Esophageal Squamous Cell Carcinoma
A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of Sintilimab for Consolidation Therapy After Radical Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04514835
- Testing
- Cisplatin+Capecitabine+Sintilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Esophagus Cancer, Stage III
GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- GiCAEC (NCT04648917)
- Testing
- Caffeic acid
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Locally Advanced Esophageal Squamous Cell Carcinoma
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
This was a single-center, open phase II clinical study. 34 patients with resectable local middle and advanced esophageal squamous cell carcinoma were treated with anti-PD-1 antibody combined with sequential chemoratherapy…
- Trial name
- NCT06843889
- Testing
- Toripalimab (240mg day1, Q3W*3cycle)
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Esophageal, Toxicity
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis during concurrent paclitaxel and carboplatin…
- Trial name
- MnSOD (NCT00618917)
- Testing
- Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Joel Greenberger
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab.
- Trial name
- NCT06718205
- Testing
- Nimotuzumab, Sintilimab, Paclitaxel-albumin
- Where
- China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Neoplasms
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
The standard non surgical therapy of locally advanced esophageal cancer is based on a definitive concurrent chemoradiotherapy regimen with fluorouracil and cisplatin.
- Trial name
- NCT00213486
- Testing
- irinotecan
- Where
- France
- Volunteers
- 43 people
- Sponsor
- University Hospital, Rouen
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Esophageal Neoplasms
Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
This phase Ⅰ/Ⅱ trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for locally advanced esophageal carcinoma.
- Trial name
- NCT02429622
- Testing
- IMRT simultaneous integrated boost, Paclitaxel, Nedaplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- PALACE-1 (NCT03792347)
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hecheng Li M.D., Ph.D
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced…
- Trial name
- NCT07266493
- Testing
- Chemotherapy （Albumin bound paclitaxel and Carboplatin）
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Sarcoma, Melanoma
A Study of PRT1419 in Patients With Advanced Solid Tumors
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer
- Trial name
- NCT04837677
- Testing
- PRT1419
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Prelude Therapeutics Incorporated
Gastric Cancer
Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens
The objective of this study is to compare the possible time savings from reduction of nursing and pharmacy time to manage AEGC patients using capecitabine-based regimens versus traditional intravenous chemotherapy in the Hong…
- Trial name
- NCT02063412
- Sponsor
- Vivian Wing Yan Lee